Writing and Amending the Clinical Protocol: IND and CTA Lifecycle Strategy for Once-Weekly Basal Insulin Analogues in Type 2 Diabetes

Basal insulin therapy remains a cornerstone of glycemic management in type 2 diabetes, but daily injection is a well-documented barrier to initiation and persistence (Polonsky & Henry, 2016). Once-weekly basal insulin analogues, engineered through albumin-binding or other half-life-extending modifications, aim to reduce injection burden while maintaining glycemic control comparable to daily basal insulin. This article is written from the perspective of a clinical trial manager carrying a once-weekly basal insulin program from its initial Investigational New Drug (IND) application or Clinical Trial Application (CTA) through subsequent protocol amendments. It reviews the disease and pharmacological rationale, best practices for trial phase and population selection including insulin-naive and insulin-experienced populations, anticipated risks and pharmacovigilance strategy with particular attention to hypoglycemia monitoring, statistical sample-size rationale drawn from registered trials, the detailed regulatory requirements and timelines governing the initial submission and amendments across FDA, Health Canada, and EMA frameworks, a representative schedule of assessments spanning a twelve-month period, and the application of artificial intelligence tools to data capture and quality. The article closes with recommendations for regulatory affairs and clinical operations professionals managing this therapeutic category.Keywords: once-weekly basal insulin; type 2 diabetes; hypoglycemia; protocol amendment; Investigational New Drug application; Clinical Trial Application; time in range; regulatory artificial intelligence